Clinical Trials
9 trialsNCT01909453 2026-02-27
COLUMBUS
Pfizer
Phase 3 Completed
NCT02967692 2025-09-18
COMBI-i
Novartis
Phase 3 Terminated
NCT05297565 2025-02-27
CheckMate-6GE
Bristol-Myers Squibb
Phase 3 Completed
NCT04410445 2023-04-21
PIVOT-12
Nektar Therapeutics
Phase 3 Terminated
NCT03445533 2022-11-08
A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma
Idera Pharmaceuticals, Inc.
Phase 3 Terminated
NCT03329846 2021-07-09
An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma
Bristol-Myers Squibb
Phase 3 Completed
NCT01763164 2021-03-22
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
Pfizer
Phase 3 Completed
NCT00434057 2012-02-14
Evaluation of Pigmented Skin Lesions With MelaFind(R) System
MELA Sciences, Inc.
Phase 3 Completed
NCT00094653 2011-07-11
MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma
Bristol-Myers Squibb
Phase 3 Completed